Stocks and Investing
Stocks and Investing
Wed, November 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Fraser Maintained (AMRX) at Strong Buy with Increased Target to $7 on, Nov 8th, 2023
Gregory Fraser of Truist Securities, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Strong Buy with Increased Target from $6 to $7 on, Nov 8th, 2023.
Gregory has made no other calls on AMRX in the last 4 months.
There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Gregory
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $5 on, Monday, August 7th, 2023
- David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $5 on, Monday, August 7th, 2023
Contributing Sources